| Autor: |
Bongiovanni, Marco, Bini, Teresa, Cicconi, Paola, Landonio, Simona, Meraviglia, Paola, Testa, Letizia, Biagio, Antonio Di, Chiesa, Elisabetta, Tordato, Federica, Biasi, Patrizia, Adorni, Fulvio, Monforte, Antonella D'Arminio |
| Zdroj: |
AIDS Research and Human Retroviruses; February 2006, Vol. 22 Issue: 2 p132-138, 7p |
| Abstrakt: |
We studied 382 multiexperienced HIV-infected patients followed up for ≥3 months after starting lopinavir/ritonavir (LPV/r) to identify the factors predicting hypertriglyceridemia and high non-HDL cholesterol levels (triglycerides ≥200 mg/dl and/or non-HDL cholesterol ≥190 mg/dl) after 6 and 12 months of LPV/r exposure. The predictors of hypertriglyceridemia were higher baseline triglyceride levels [OR: 2.28 (95% CI: 1.67–3.12) for each additional 100 mg/dl; p = 0.001], the total duration of antiretroviral treatment [OR: 1.26 (95% CI: 1.12–1.41) for each additional year; p = 0.01], CDC stage C (OR: 2.06; 95% CI: 1.24–3.88; p = 0.02), and male gender (OR: 2.52; 95% CI: 1.42–4.74; p = 0.02); intravenous drug abusers seem less likely to develop the event (OR: 0.52; 95% CI: 0.37–0.92; p = 0.03). The predictors of high non-HDL cholesterol levels were higher baseline levels [OR: 3.92 (95% CI: 1.92–6.24) for each additional 100 mg/dl; p = 0.001) and the combination of NRTIs and NNRTIs with LPV/r (OR: 1.83; 95% CI: 1.10–3.69; p = 0.03). The 75 patients stopping LPV/r showed a significant reduction in median triglyceride and non-HDL cholesterol levels after 3 months of 39 mg/dl and 20 mg/dl (p = 0.01 for both), respectively. Patients with high triglyceride and non- HDL cholesterol levels at the start of LPV/r treatment are at higher risk of developing hyperlipidemia. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
